The SGLT2 inhibitor dapagliflozin did not result in a reduced incidence of organ failure or death in patients with cardiometabolic risk factors who were hospitalized with COVID-19, according to the phase III DARE-19* trial. However, this finding does not support discontinuation of SGLT2 inhibitors in COVID-19 patients.
Patients with depression, antidepressant or antipsychotic medication use, insomnia, and anxiety disorders are more likely to develop type 2 diabetes (T2D) than those without these exposures, according to a study.
Using the hyperinsulinaemic-euglycaemic clamp as the gold-standard for assessment, recent research has shown that insulin resistance (IR) may be causally linked to left ventricular (LV) diastolic and systolic dysfunction in patients with type 2 diabetes mellitus (T2DM).
In patients with diabetes, plasma heparin cofactor II (HCII) activity is inversely associated with glomerular injury and may serve as a biomarker for early-stage diabetic kidney disease, a new study has found.
Men who regularly consume inflammation-inducing foods, such as red meat, processed food, fried foods, and sugar-sweetened beverages, among others, tend to have an increased risk of testosterone deficiency (TD), suggests a study.
Among patients with newly diagnosed type 2 diabetes, the risk of developing cardiovascular disease (CVD) is elevated in the presence of symptoms indicative of diabetic polyneuropathy, as shown in a study.
The incidence of severe liver disease, hepatic failure, and toxic liver disease is comparable between ulipristal acetate and (UPA) gonadotropin-releasing hormone (GnRH) agonists, reports a recent study. However, patients on UPA have a higher rate of mild liver disease than those in the GnRH agonist group.